Immune Checkpoint FGL1 Expression of Circulating Tumor Cells Is Associated With Poor Survival in Curatively Resected Hepatocellular Carcinoma

• Published in: Frontiers in oncology Vol. 12; p. 810269
• Main Authors: Yan, Qing, Lin, Hao-Ming, Zhu, Ke, Cao, Yi, Xu, Xiao-Lin, Zhou, Zi-Yu, Xu, Lei-bo, Liu, Chao, Zhang, Rui
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 22.02.2022
• Subjects: circulating tumor cells; clinical application; FGL1; hepatocellular carcinoma (HCC); immunotherapy; Oncology; hepatocellular carcinoma (HCC); clinical application; circulating tumor cells; FGL1; immunotherapy

LAG-3 is one of the common tumor immune checkpoints. LAG-3 can inhibit the activation and proliferation of T cells, and can also suppress immunity by regulating other immune-related cell functions. FGL1 was recently discovered to be the main ligand of immune checkpoint LAG-3 and play a critical role...